3 completed, 1 enrolling by invitation. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Enrolling by invitation 1 |
Follow JNJ-64264681: new trials by email Literature Review of JNJ-64264681 trials Research Report on JNJ-64264681
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring JNJ-75348780, JNJ-67856633, JNJ-54179060 - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Enrolling by invitation | Janssen Research & Development, LLC | 120 | 2024-12-30 | 2026-09-25 |
| A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia JNJ-64264681, JNJ-67856633 - Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Janssen Research & Development, LLC | 75 | 2021-02-25 | 2025-08-21 |
| A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia JNJ-64264681 - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Completed | Janssen Research & Development, LLC | 85 | 2020-07-02 | 2025-08-21 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants JNJ-64264681, Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 105 | 2018-07-31 | 2025-02-03 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1)
Janssen Research & Development, LLC (4)
Belgium (3) · Georgia (3) · Moldova (3) · Poland (3) · Ukraine (3) · Australia (2) · France (2) · Israel (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · United States (2) · Denmark (1) · Greece (1)
2018 (1), 2019 (1)